News & Updates

In the placebo-controlled ORBITA-COSMIC* trial, an implantable coronary sinus reducer (CSR) does not increase transmural myocardial perfusion, but it reduces the frequency of angina and improves quality of life (QoL) in patients with no further antianginal options.

Children of mothers who took n‒3 long-chain polyunsaturated fatty acid (LCPUFA) supplements during pregnancy tend to have an increased body mass index (BMI) at age 10 years, a higher risk of being overweight, and greater fat percentage and metabolic syndrome score, a study has shown.

Patients with ankylosing spondylitis who are exposed to higher doses of nonsteroidal anti-inflammatory drugs (NSAIDs) appear to have an elevated risk of cardiovascular disease (CVD), according to a study.

A recent study has found three baseline characteristics that can predict sustained acute kidney injury (AKI), and these include estimated glomerular filtration rate (eGFR), loop diuretic, and spironolactone use. For immune checkpoint inhibitor-related AKI, only baseline eGFR is predictive.

The use of nasal spray zavegepant 10 mg provides freedom from pain and the most bothersome migraine symptom (MBS*) at 2 hours after treatment in women with acute migraine, according to the pooled analysis of the two trials presented at AAN 2024.

A pharmacist monitoring program is feasible and useful for patients receiving oral antineoplastic agents, reports a recent study.

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.